Objective: The aim of this study was to determine the effects of estrogen therapy (ET) on carotid artery inflammation when initiated early and late relative to surgical menopause.
T he presence of immune cells, particularly macrophages and T cells, is a common characteristic of developing atherosclerotic lesions. 1 Activated macrophages produce inflammatory cytokines that mediate pro-inflammatory effects through both innate and adaptive immunity. Most activated T cells in atheromas are CD4 + T cells, 2 which contribute to the progression of atherosclerosis in atherosclerosis-prone mice. 3 CD8 + T cells are less common in atheromas, and their role in atherogenesis is less well understood. Various types of activated T cells influence adaptive immunity by producing pro-inflammatory cytokines, anti-inflammatory cytokines, or both. T helper-1 (Th-1) cells (major activated T cells in lesions) produce proatherogenic cytokines such as interferon-F (IFN-F), tumor necrosis factor-> (TNF->), and interleukin-2 (IL-2), whereas Th-2 cells may oppose Th-1 effects by secreting the anti-inflammatory cytokines IL-4 and IL-10. 1 During early T-cell development, under certain circumstances, Th-1 and Th-2 cells can switch their cytokine expression patterns. 4 Estrogen seems to influence atherogenesis and cardiovascular disease through multiple mechanisms because it alters various vasoactive molecules, lipid concentrations, and antioxidant, coagulation, and fibrinolytic systems. 5 Although estrogen therapy (ET) may produce beneficial effects on plasma lipoprotein concentrations, the changes explain less than half of the atheroprotective effects of estrogen, 6 suggesting a large lipid-independent effect. Estrogen has anti-inflammatory properties, reducing circulating levels of monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1, 7, 8 probably in part through transcription factor cross-talk involving estrogen receptor (ER) antagonism of NF-JB activity. 9 ER-> and ER-A are present within the arterial wall, and there is evidence for the direct effects of estrogens on arteries and arterial cells. 10<12 ERs are also expressed by immune cell populations. 13 Data from observational studies in women and experimental studies in animals provide support that estrogen protects against coronary heart disease (CHD) and atherosclerosis. 6, 14 Some of the earliest evidence that the atheroprotective effects of estrogens may be attenuated in late menopause once atherosclerosis was well established came from our own work in the ovariectomized nonhuman primate model. 15, 16 Subsequently, data from the Women's Health Initiative (WHI), a randomized controlled trial, demonstrated a lack of beneficial effects of estrogenprogestogen therapy overall and adverse effects on clinical CHD outcomes in the first year of treatment of older postmenopausal women. 17, 18 Secondary analyses of the WHI found a significant graded relationship between the years since menopause and the relative hazard for CHD among women who received ET or estrogen-progestogen therapy compared with placebo; the hazard ratio (95% CI) for women assigned to hormone therapy within 10 years of menopause was 0.76 (0.50-1.16) compared with 1.28 (1.03-1.58) for women assigned to hormone therapy 20 years or later after menopause. 19 The Btiming hypothesis[ emerged from these and other data, which suggested that the stage of atherosclerosis, timing of initiation of ET relative to menopause, or both might be important determinants of estrogen's ability to favorably affect atherosclerosis. 20 The present study was designed to test the timing hypothesis in a prospective manner in cynomolgus monkeys, a wellestablished nonhuman primate model of women's health and atherosclerosis. 20 Cynomolgus monkeys are similar to women in reproductive system function, including a regular 28-day menstrual cycle and similar gonadotropin and sex hormone variations across the cycle. Like women, female cynomolgus monkeys are protected against the development of CHD premenopausally and lose that protection postmenopausally. 21 We hypothesized that estrogen treatment would inhibit atherogenesisassociated arterial inflammatory responses when administered early after ovariectomy, but not after an extended estrogendeficient period.
METHODS

Animals and experimental design
The purpose of the present study was to assess the atheroprotective effects of estrogen when administered early (1 mo) and late (54 mo or 4.5 y) after surgical menopause in ovariectomized female cynomolgus monkeys (Macaca fascicularis). The animals were obtained through the Institut Pertanian Bogor (Jakarta, Indonesia). Age was estimated by dentition at the time of importation. For the early menopausal cohort, 24 monkeys were fed an atherogenic diet containing 35% of calories from fat (predominantly saturated fat) with 0.20 mg of cholesterol per calorie, 46% of calories from carbohydrate, and 19% of calories from protein (casein and lactalbumin) for 6 months before ovariectomy and randomization to control or estradiol (E 2 ) at 1 month after ovariectomy. The late menopausal cohort consisted of 34 monkeys that were ovariectomized and that consumed an atherogenic diet for 4.5 years before randomization to receive control or E 2 . E 2 -treated monkeys received a human equivalent dose of oral micronized E 2 1 mg/day for 8 months before necropsy. Blood samples were obtained at baseline, before E 2 administration, and periodically throughout the study, and carotid arteries and other tissues were obtained at necropsy. Animals were housed in social groups of four to six monkeys each. One animal in the early menopausal cohort died of unknown causes 4 months after ovariectomy. All procedures were conducted in compliance with state and federal laws, standards of the US Department of Health and Human Services, and regulations and guidelines established by the Wake Forest University Animal Care and Use Committee. Wake Forest University is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Necropsy and arterial processing
At the end of the treatment period, the monkeys were deeply sedated with pentobarbital (30 mg/kg IV) and euthanized. The carotid arteries were removed, cleaned of adherent connective tissues, opened longitudinally, and sectioned. The common carotid arteries were subdivided into individual segments and processed as previously described for iliac arteries. 22 Briefly, adjacent segments were flash frozen in liquid nitrogen for RNA isolation and fixed in 4% paraformaldehyde for histologic examination. Proximal sections were cryopreserved in optimal cutting temperature (OCT) embedding medium for immunohistochemical analyses.
Morphologic and immunohistochemical analyses of arterial segments
Atherosclerosis was determined as previously described. 22, 23 Briefly, paraffin blocks were sectioned at 5 Km and stained with Verhoeff Van Gieson stain and H&E stain for assessment of tissue histology. Plaque areas (mm 2 ) of the carotid artery sections were determined by computer-assisted histomorphometric methods using Image Pro Plus software 22 (Media Cybernetics Inc., Silver Springs, MD).
Immunohistochemical staining was performed on paraffin and OCT-embedded carotid artery biopsy sections. Sections were cut at 5 Km thickness, dried overnight at room temperature (RT), and stored at j20-C. Serial sections were stained for (1) H&E stain, (2) CD4 (T cells), (3) CD8 (T cells), (4) Ham56 (macrophages), and (5) CD68 (macrophages). OCT-embedded sections of the colon (CD4 and CD8) and liver (Ham56 and CD68) were used as positive control tissues ( Fig. 1 ). For immunohistochemical staining, sections were brought to RT and fixed in cold acetone for 10 minutes. Epitopes were detected using the following commercially available primary monoclonal antibodies: mouse anti-human CD4 (1:100 L200 clone; BD Pharmingen, San Jose, CA), mouse anti-human CD8 (1:10 RPA-T8 clone; BD Pharmingen), mouse anti-human Ham56 (1:1 Ham56; DAKO, Carpinteria, CA), and mouse anti-human CD68 (1:100 Y1/82A clone; BD Pharmingen). Primary antibodies were localized with appropriate biotinylated secondary antibodies (BioGenex Inc., San Ramon, CA), streptavidin-alkaline phosphatase (BioGenex Inc.), and Vector Red substrate (Vector Laboratories, Burlingame, CA). Tissue sections were incubated in primary antibody for 1.5 hours at RT, in secondary antibody for 20 minutes at RT, and in streptavidin-alkaline phosphatase for 20 minutes at RT, followed by Vector Red chromagen for 3 minutes. Sections were counterstained with Mayer's hematoxylin and examined by light microscopy. Immunohistochemical cell staining was quantified using computer-assisted morphometry (Image Pro Plus 5.1). A grid filter (8.5 Km 2 ) was applied to digitize images, and each cross-hatch within the intima was evaluated for pos-itive or negative staining. Staining density was expressed as the percentage of intima occupied by positive cell staining. Tissue paraffin blocks were cut at 5 Km and deparaffinized. Sections were stained with Verhoeff Van Gieson or H&E stain for assessment of tissue histology. Plaque areas (mm 2 ) of the carotid artery sections were determined by computer-assisted histomorphometric methods using Image Pro Plus software 22 (Media Cybernetics Inc.). All measures were made by a trained observer blinded to both treatment groups.
Plasma lipid measurements
Total plasma cholesterol (TPC), high-density lipoprotein cholesterol (HDLc), and plasma triglycerides (TGs) were determined in the Wake Forest Primate Center Clinical Chemistry Laboratory using reagents (ACE cholesterol, ACE HDLc, and ACE TGs) and instrumentation (ACE ALERA autoanalyzer) from Alfa Wasserman Diagnostic Technologies (West Caldwell, NJ). Cholesterol and HDLc were standardized to calibrated controls from the Centers for Disease Control and PreventionY National Institutes of Health Lipid Standardization Program. Intra-assay and inter-assay coefficients of variation were less than 5% for all analytes. Non-HDLc, which approximates the sum of low-density lipoprotein (LDL) cholesterol and very LDL cholesterol, was calculated by subtracting HDLc from TPC.
Serum E 2 measurements
Serum E 2 was determined in ether-extracted serum samples from fasted animals using a radioimmunoassay from Diagnostic Systems Laboratories, as previously described. 8 
RNA isolation and quantification
RNA was isolated from carotid artery sections as described previously, 23 followed by a cleanup step on Qiagen RNeasy columns. Samples were assessed for total RNA concentration and purity using ND-1000 Spectrophotometer (NanoDrop; Fisher Thermo, Wilmington, DE). Total RNA (2 Kg) was reverse transcribed to generate complementary DNA (cDNA) archive using a high-capacity cDNA archive kit (Applied Biosystems). Quantitative real-time reverse transcription polymerase chain reaction (PCR) assays were performed on an ABI Prism 7500 FAST system using macaque-specific TaqMan FAM-MGB primer probe assays for CD3, CD4, CD8, CD25, CD56 or neural cell adhesion molecule-1, CD83, CD163, forkhead box P3 (FoxP3), IL-2, IL-4, IL-10, TNF->, IFN-F, matrix metalloproteinase-9 (MMP-9), MCP-1, chemokine (C-C motif) receptor 6, ER-> and ER-A or human-specific CD68, type I collagen (Col1), and smooth muscle >-actin (ACTA2; Applied Biosystems). 8, 22 Individual PCRs were performed using cDNA generated from 27 ng of total RNA. All quantitative reverse transcription PCR data were normalized to the mean of the endogenous control genes GADPH (glyceraldehyde-3phosphate dehydrogenase) and A-actin using the 2 j$C T procedure. 24 Target amplifications not reaching threshold by 40 cycles were designated as zero expression.
Statistical analysis
All data were assessed for normality and transformed if necessary. Data are presented as mean (95% CI). Baseline characteristics immediately before E 2 administration were analyzed using Student's t test. Posttreatment lipid profiles and body weight were analyzed using analysis of covariance (ANCOVA) after controlling for baseline lipid measures. Relationships between baseline lipid measures and gene expression data or carotid intima area were assessed within individual cohorts by r. ANCOVA was used to assess the main effects of treatment and menopause on gene expression data and carotid intima area; tests for interactions were used to examine the consistency of treatment effects between menopausal cohorts. In accordance with a priori strategies for analysis developed because the early and late menopausal cohorts represented unique experimental conditions, differences in gene expression data between the control group and the E 2 treatment group were investigated within individual cohorts using Student's t test. r values between molecular endpoints and posttreatment lipids were also determined. The level of significance was set at P e 0.05. All analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL). Correlations between immunohistochemical and gene expression data were determined using Spearman rank order correlation analysis.
RESULTS
Baseline measurements
There were no significant baseline differences in body weight or in plasma TPC, TG, HDLc, and non-HDLc concentrations in either menopausal cohort between control and E 2 -treated animals ( Table 1) .
Posttreatment measurements
The mean body weights of E 2 -treated animals were less than those of controls in the late menopausal cohort. However, the correlations between body weights and lipid profile and gene expression data were statistically similar between cohorts (all P 9 0.05; data not shown). In the early menopausal group, plasma TPC and non-HDLc concentrations were significantly decreased in the E 2 -treated group compared with controls. In the late menopausal cohort, plasma HDLc concentrations were significantly decreased and plasma TG concentrations were significantly increased in the E 2 -treated group compared with controls ( Table 2) .
Gene expression measures
Expression of inflammatory markers in the carotid artery is presented in Table 3 . The two-factor analysis of variance revealed significant main effects of the treatment of all inflammatory markers, but not ACTA2 and ER-> (Table 4 ). There was no significant interaction between treatment and time since menopause, except for the macrophage marker CD163 (P = 0.046). We also examined the mean E 2 -to-control expression ratio of each inflammatory marker, using ANCOVA, to adjust for pretreatment plasma lipids. Carotid artery expression levels of the macrophage markers CD68 and CD163, the dendritic cell marker CD83, and the natural killer (NK) cell marker neural cell adhesion molecule-1 were all significantly lower in E 2 -treated monkeys than in controls in the early menopausal cohort but not in the late menopausal cohort (Table 4 ). Transcription levels of markers for T cells (CD3), T-effector cells (CD4), cytotoxic T cells (CD8), and CD25 (Tregs and others) were significantly lower in the E 2 group in both early and late menopausal cohorts. No significant effect of E 2 was observed for the expression of FoxP3, a key marker for T-regulatory cells. Transcription levels of chemokine (C-C motif) receptor 6, The differences between the geometric means of the control and E 2 groups were assessed with analysis of covariance after controlling for pretreatment lipid profiles. E 2 , estradiol; TPC, total plasma cholesterol; HDLc, high-density lipoprotein cholesterol; TGs, triglycerides. a marker for both Th-1 and Th-17 cells, were decreased in the E 2 group in the late menopausal cohort only.
Cytokines and other markers
Transcript levels for the pro-inflammatory cytokine IFN-F and the anti-inflammatory mediator IL-4 were significantly lower in E 2 -treated monkeys in the early menopausal cohort but not in the late menopausal cohort. Transcript levels for the chemokine MCP-1, the pro-inflammatory cytokine TNF->, and the anti-inflammatory mediator IL-10 were significantly lower in E 2 -treated monkeys in both cohorts.
MMP-9 was significantly lower in E 2 -treated monkeys than in controls in both cohorts. Expression of Col1 was significantly lower in the E 2 -treated group in both menopausal cohorts. Expression of ER->, ER-A, and smooth muscle >-actin did not significantly differ between E 2 -treated monkeys and controls in either cohort.
Relationships between immune cell staining densities and arterial gene expression measures
Intimal immunohistochemical staining of markers for macrophages and T cells was significantly correlated with corre-sponding measures of the expression of macrophages and T-cell markers measured in a distal segment of the carotid artery. Intimal CD68 + staining was correlated with messenger RNA (mRNA) levels for CD68 (r = 0.45, P G 0.001), which was used as a molecular marker for macrophage content. Intimal CD4 + staining density was correlated with CD4 mRNA levels (r = 0.33, P G 0.05). Intimal CD8 + staining density was highly correlated with CD8 mRNA expression (r = 0.40, P G 0.01).
DISCUSSION
In this study, the effects of estrogen on the expression of genes relevant to atherosclerosis in the carotid artery depended on whether treatment was initiated at an early stage or after many years of estrogen deficiency. Arterial macrophages, dendritic and NK cell markers, and pro-inflammatory cytokines were significantly decreased in monkeys treated with E 2 early after menopause, an effect that was not observed or was dampened in the late menopausal cohort. In contrast, estrogen treatment in both early and late menopausal cohorts resulted in a lower expression of T-cell markers, including Th cells and cytotoxic T cells. The current results support the hypothesis that the timing of estrogen treatment relative to menopause has a profound impact on the vascular effects of estrogens, which may be mediated in part by differential immune modulation of events within the arterial wall. The mechanism by which E 2 preferentially reduced arterial macrophage content in the early menopausal group but not in the late menopausal group is unclear but may relate to the differential nature of the lesions. In the late menopausal monkeys, lesions had developed and evolved over many years of estrogen deficiency and may have been relatively resistant to treatment.
The diversity of immune cells in plaques, reflecting both innate and adaptive immune responses, is a distinctive feature of atherosclerosis. Macrophages are critical components of the initiating and ongoing inflammatory processes in atherogenesis and of the progression from early fatty streaks to vulnerable atherosclerotic plaques. Macrophages and dendritic cells accumulate in atherosclerotic plaques and rupture-prone lesions, 25 and contribute to innate and adaptive immune responses. Macrophages take up modified LDL through scavenger receptors and may become foam cells. Activated macrophages and dendritic cells generate pro-inflammatory cytokines, which recognize and present foreign antigens to naive T cells. Activated T cells in atherosclerotic plaques have predominantly Th-1 properties and generate cytokines IFN-F, IL-2, and TNF->. 26 IFN-F, also elaborated by NK cells and macro-phages,seems to promote atherogenesis. In one report, apolipoprotein EYdeficient and LDL receptorYdeficient mice lacking IFN-F exhibited attenuated atherosclerosis. 27 IFN-F contributes to the recruitment of T cells and macrophages to plaques, augments class II histocompatibility expression, and enhances secretion of Th-1Ypromoting cytokines. Th-2 cells secrete IL-4, IL-5, IL-10, and IL-13, and generally oppose Th-1 responses, although their role in atherogenesis is controversial. 28 Regulatory T cells (CD4 + and CD25 + ) modulate Th-1 effects by secreting anti-inflammatory cytokines. The roles of cytotoxic T cells (CD8 + ) and NK cells in atherosclerosis are not well understood. 1 Arterial intimal lesion size (cross-sectional area) is a classic measurement of atherosclerosis in our nonhuman primate model, which develops over relatively long periods of time. As we expected, there was no significant difference in carotid intima area between control and treated animals in either cohort of animals after 8 months, a short duration of treatment. However, this metric provides little information on the metabolic characteristics of the lesion. Exploration of arterial gene expression is a sensitive means for evaluating intra-arterial cellular and molecular events and provides data that may elucidate mechanisms of pathogenesis and improve prediction of treatment efficacy and disease progression, with the prospect of fostering new clinical strategies. We assessed the scavenger receptors CD68 and CD163 as macrophage markers. Although CD68 is The main effect of menopause status and treatment on carotid gene expression was analyzed by factorial analysis of covariance after controlling for correlated lipid profile. E 2 , estradiol; FoxP3, forkhead box P3; CCR6, chemokine (C-C motif) receptor 6; NCAM-1, neural cell adhesion molecule-1; Col1, type I collagen; MCP-1, monocyte chemoattractant protein-1; IFN-F, interferon-F; TNF->, tumor necrosis factor->; IL, interleukin; MMP-9, matrix metalloproteinase-9; ER, estrogen receptor. also expressed to some extent by other cell types (such as dendritic cells), CD163 expression is relatively restricted to the monocyte/macrophage lineage in general and to resident tissue macrophages with an M2-like anti-inflammatory phenotype. 29 CD83 is a marker for mature dendritic cells but also is expressed in other cell types such as CD8 + T cells and B cells. 30 CD3, CD4, and CD8 are T-cellYspecific markers, with CD3 being present in most T cells, whereas CD4 and CD8 are found in T-helper cells and cytotoxic T cells, respectively. Expression of both CD3 and CD25 is used as a marker for regulatory T cells.
Our studies suggest that early administration of estrogen relative to menopausal onset reduced arterial macrophages (CD68 and CD163), dendritic cells (CD83), and NK cells (CD56). In contrast, E 2 treatment resulted in a reduced arterial expression of markers for T cells (CD3), Th cells (CD4), cytotoxic T cells (CD8), and regulatory T cells (CD4 + and CD25 + ) in both early and late menopausal cohorts. Notably, expression of chemokine receptor 6 (a C-C chemokine receptor expressed in Th-17, Th-1, and unactivated memory T cells) was reduced in the late menopausal cohort alone. E 2 had no effect on FoxP3, a marker for adaptive and natural regulatory T cells that is also transiently expressed in some other activated CD4 + cells. 31 Importantly, levels of expression of the genes used as markers for individual cell types were significantly correlated with immunohistochemical staining for the corresponding marker in adjacent arterial sections. Gene expression analysis is a useful method for measuring molecular events occurring in a larger representative section of the artery than feasible with immunohistochemical analysis, which generally relies on a single 5-to 7-Km section of artery per specific antibody. The intima-media segments of artery used for gene expression in this experiment corresponded to approximately 1,000 microtome sections of 5 Km each. In this context, gene expression assay represents a useful tool for characterizing more globally the presence of specific cell types within atherosclerotic lesions, as this method allows for a more complete characterization of the segment examined. The composition of atherosclerotic lesions changes dynamically as the disease progresses. Early lesions are characterized by an accumulation of intracellular or extracellular lipids and the presence of macrophage foam cells and possibly vascular smooth muscle cells (VSMCs) containing lipid droplets. 32 Accumulation of lipids, cells, and matrix components, which are often associated with structural disorganization, repair, intimal thickening, and deformity of the arterial wall, is a common feature of advanced lesions. 33 The proliferation and accumulation of VSMCs are often seen in such lesions. VSMCs may switch their phenotypes from a contractile state to a synthetic state and produce significant amounts of extracellular matrix components such as Col1 and type III collagen, which are abundant in plaques. 34 VSMCs may also produce pro-inflammatory mediators such as MCP-1 and MMPs. MMPs and other proteases are also secreted by inflammatory cells, ultimately degrading the extracellular matrix. This process results in tissue remodeling in developing atheromas and plaque rupture in vulnerable plaques. 35 Vulnerable plaques and unstable lesions often contain numerous inflammatory cells at lesion edges and are often rich in lipids, with fewer VSMCs than stable lesions. 36 Although E 2 did not influence smooth muscle >-actin expression, it was associated with a significantly lower expression of Col1 in the early menopausal cohort. Therefore, early administration of E 2 seems to attenuate both inflammation and extracellular matrix deposition (significant features of plaque progression) while apparently not influencing VSMC content.
A balance between arterial pro-inflammatory cytokine expression and arterial anti-inflammatory cytokine expression is a probable determinant of the ultimate fate of atherosclerotic lesions. Pro-inflammatory cytokines such as IFN-F, TNF->, and others may promote atherogenesis and increase lesion complexity, whereas anti-inflammatory cytokines such as IL-4 and IL-10 may limit these processes and inhibit disease progression. Estrogen seemed to reduce the expression of both proinflammatory and anti-inflammatory mediators examined here. In addition, IL-10, a pleiotropic anti-inflammatory cytokine expressed by many cell types within the adaptive immune system, 37 was decreased in the E 2 groups in both early and late menopausal cohorts.
The anti-inflammatory response of E 2 observed here could occur through modulation of the activity of the nuclear transcription factor NF-JB, which regulates the expression of adhesion molecules, cytokines, and chemokines within developing atheromas. 38 Estrogen can inhibit NF-JB signaling via ERs through a variety of mechanisms. 39 ERs are expressed in the arteries in cynomolgus macaques and are inversely correlated with atherosclerosis extent. 23 Nevertheless, in this study, ER-> and ER-A gene expression was not diminished in the late menopausal group compared with the early menopausal group.
CONCLUSIONS
This study directly addresses, for the first time, the timing hypothesis in an animal model by exploring arterial responses to estrogen treatment in nonhuman primates with short (1 mo) and long (4.5 y) postmenopausal periods of estrogen deficiency before initiation of estrogen treatment. These periods correspond to about 3 months and 12 to 15 years, respectively, in women. The exact ages of the animals were unknown, limiting our ability to assess the impact of age on the outcomes. Nevertheless, all animals were premenopausal at ovariectomy and thus would be representative of women younger than 50 years. Clinically, ET generally begins with the onset of menopause to treat hot flushes and other menopausal symptoms and would rarely be delayed and introduced later except in the context of a randomized trial. The findings from this unique experimental design support the idea that estrogen inhibits inflammation in arteries of animals after a short menopausal interval but not after a long menopausal interval. This effect seems to be limited to selected targets and cell populations; E 2 -treated monkeys had reduced expression of IFN-gamma and markers for arterial macrophages and dendritic cells in the early menopausal group but not in the late menopausal group, whereas arterial T-cell marker expression was lower in the E 2 -treated groups in both early and late menopause. Arterial MMP-9 was reduced by estrogen treatment in both groups, arguing against the theory that estrogen might increase risk of cardiovascular events when initiated in late menopause by increasing arterial plaque expression of MMP-9 and destabilizing lesions. These findings bring new information to the clinically important field of hormone replacement and cardiovascular disease and may help to explain the relative lack of benefit on older women in the WHI.
